LLY vs JNJ: Eli Lilly and Company vs Johnson & Johnson
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | LLY | JNJ |
|---|---|---|
| Company | Eli Lilly and Company | Johnson & Johnson |
| Price | $1,179.11 | $253.04 |
| Market Cap | $1.05T | $609.12B |
| P/E Ratio | 41.84 | 29.32 |
| EPS | $28.18 | $8.63 |
| Dividend Yield | 59.00% | 2.12% |
| 52-Week High | $1,249.45 | $269.43 |
| 52-Week Low | $623.78 | $162.78 |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYQ | NYQ |
| Employees | 50,000 | 138,200 |
Eli Lilly and Company and Johnson & Johnson both operate in the Healthcare sector. LLY trades at a market cap of $1.05T against JNJ's $609.12B. Valuation-wise, LLY carries a trailing P/E of 41.84 versus 29.32 for JNJ. How these figures compare depends on each company's growth profile, margins and outlook — the snapshot above is a starting point for further research, not a recommendation.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Eli Lilly and Company and Johnson & Johnson. This is not financial advice.
Recommended Reading & Tools
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →Roger Lowenstein's definitive biography of the world's most famous investor.
Check Price →Data snapshot: 18 July 2026 (Yahoo Finance) · Page last built: